InflaRx N.V. (IFRX) vs Keros Therapeutics, Inc. (KROS)
A side-by-side comparison of InflaRx N.V. and Keros Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IFRX
InflaRx N.V.
$1.58HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
KROS
Keros Therapeutics, Inc.
$11.01HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — IFRX vs KROS
growth of $100 · dividends reinvested · last 6yIFRX -65.8% (-16.4%/yr)KROS -42.6% (-8.8%/yr)KROS compounded faster over this window
IFRX KROS
IFRX vs KROS: by the numbers
- •IFRX is the larger company ($233M vs $218M market cap).
- •Both run net losses; KROS's is the smaller (-553.88% vs -155582.08% net margin).
Metrics side by side
Valuation
| Metric | IFRX | KROS |
|---|---|---|
| P/S ratio | N/A | 14.54 |
| P/B ratio | 1.39 | 0.83 |
Profitability
| Metric | IFRX | KROS |
|---|---|---|
| Gross margin | -24677.94% | 94.68% |
| Operating margin | -164525.50% | 28.94% |
| Net margin | -155582.08% | -553.88% |
| ROE | -27.27% | -31.70% |
| ROIC | -25.38% | -36.49% |
Growth (annualized)
| Metric | IFRX | KROS |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 172.50% |
| Total return CAGR (5Y) | -7.34% | -21.98% |
Frequently asked
- How have IFRX and KROS total returns compared?
- Over the past 5 years, IFRX delivered -7.34% and KROS delivered -21.98% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
InflaRx ROEKeros Therapeutics ROEInflaRx operating marginKeros Therapeutics operating marginInflaRx revenue growthKeros Therapeutics revenue growthInflaRx free cash flowKeros Therapeutics free cash flow
InflaRx & Keros Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.